MannKind sends insulin to FDA

Two months after releasing Phase III data over its inhaled insulin, MannKind announced Monday it has resubmitted its FDA application for Afrezza.

The FDA rejected the drug three years ago when the manufacturer submitted data that predated an inhaler change.

Clearing the FDA would put Afrezza on previously trod ground. Pfizer abandoned its inhaled insulin Exubera following poor sales. Novo and Lilly have also left inhaled insulin efforts in the dust.

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.